Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.

The aim of the present study was to produce glycosylation variants of the therapeutic Lewis Y-specific humanized IgG1 antibody IGN311 to enhance cell-killing effector function. This was achieved via genetic engineering of the glycosylation machinery of the antibody-producing host. Antibody genes were transiently cotransfected with acetyl-glycosaminyltransferase-III genes into human embryonic kidney-EBV nuclear antigen cells. A control wild-type antibody, IGN311wt, was expressed in the same host using identical expression vectors, but without cotransfection of genes for acetyl-glycosaminyltransferase-III expression. Both expression products were purified to homogeneity and characterized. The glyco-engineered expression product (IGN312-Glyco-I) showed a remarkably homogenous N-linked glycosylation pattern consisting of one major hybrid-type, non-fucosylated and agalactosylated form carrying a bisecting GlcNAc-group. Wild-type expression product (IGN311wt) on the other hand was glycosylated by a multitude of different core-fucosylated complex-type structures of variable degrees of galactosylation. Target affinity of the glyco-engineered antibody as well as heavy and light chain assembly were not affected by acetyl-glycosaminyltransferase-III expression. In vitro experiments showed a approximately 10-fold increase of antibody-dependent cellular cytotoxicity of the glyco-engineered antibody using different Lewis Y-positive target cancer cell lines (SK-BR-3, SK-BR-5, OVCAR-3, and Kato-III). Complement-mediated cytotoxicity of IGN312-Glyco-I was 0.4-fold reduced using SK-BR-5 as target cell line. The reduction of complement activation could be prevented and even converted into a slight increase of activity by using a different molecular-biological approach directing the glycosylation towards increased levels of complex N-linked oligosaccharides of bisected, non-fucosylated type, as a result of cotransfection of mannosidase II together with acetyl-glycosaminyltransferase-III.

[1]  L. Buck,et al.  Enhancement of therapeutic protein in vivo activities through glycoengineering , 2003, Nature Biotechnology.

[2]  PETER W. RUNSTADLER,et al.  The Importance of Cell Physiology to the Performance of Animal Cell Bioreactors , 1992, Annals of the New York Academy of Sciences.

[3]  R. Graziano,et al.  Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies , 1997 .

[4]  J. Murray,et al.  Monoclonal antibody therapy for solid tumors. , 2000, Cancer treatment reviews.

[5]  B. Shopes,et al.  A genetically engineered human IgG mutant with enhanced cytolytic activity. , 1992, Journal of immunology.

[6]  V. Sexl,et al.  Antibodies Directed against Lewis-Y Antigen Inhibit Signaling of Lewis-Y Modified ErbB Receptors , 2004, Cancer Research.

[7]  Kazuya Yamano,et al.  Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. , 2004, Biotechnology and bioengineering.

[8]  D. King,et al.  High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.

[9]  S. Hakomori,et al.  Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. , 1992, The New England journal of medicine.

[10]  B. Yin,et al.  Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer , 1996, International journal of cancer.

[11]  Margit Jeschke,et al.  Determination of the Origin of Charge Heterogeneity in a Murine Monoclonal Antibody , 2000, Pharmaceutical Research.

[12]  S. Hakomori,et al.  Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. , 1986, Cancer research.

[13]  R. Graziano,et al.  FcγR in Cytotoxicity Exerted by Mononuclear Cells (Part 1 of 2) , 1989 .

[14]  H. Scherthan,et al.  Gene Transfer and Amplification in CHO Cells , 1996, Annals of the New York Academy of Sciences.

[15]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[16]  H. Katinger,et al.  Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting. , 2000, Biotechnology and bioengineering.

[17]  G. Trempe.  Human breast cancer in culture. , 1976, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[18]  R. Ueda,et al.  Analysis of the fine specificities of 11 mouse monoclonal antibodies reactive with type 2 blood group determinants. , 1990, Molecular immunology.

[19]  M. Vásquez,et al.  Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys. , 1993, Cancer research.

[20]  R. Jefferis,et al.  IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation , 1998, Immunological reviews.

[21]  J. Murray,et al.  Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens , 1997, International journal of cancer.

[23]  T. Logtenberg,et al.  High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6 , 2003, Biotechnology progress.

[24]  J. Whang‐Peng,et al.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. , 1983, Cancer research.

[25]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[26]  E. Gelfand.  Antibody-directed therapy: past, present, and future. , 2001, The Journal of allergy and clinical immunology.

[27]  F. Hesse,et al.  Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. , 2000, Trends in biotechnology.

[28]  W. Noé,et al.  Appropriate mammalian expression systems for biopharmaceuticals. , 1998, Arzneimittel-Forschung.

[29]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[30]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. , 1992, Biotechnology.

[31]  K. Hellström,et al.  Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Baars,et al.  Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.

[33]  R. Marcus,et al.  Monoclonal antibody therapy for lymphoma. , 2003, Blood reviews.

[34]  H. Schachter.  Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. , 1986, Advances in experimental medicine and biology.

[35]  K. Sakakibara,et al.  Establishment of cultured cell lines derived from a human gastric carcinoma. , 1978, The Japanese journal of experimental medicine.

[36]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[37]  Kouhei Tsumoto,et al.  Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. , 2004, Journal of molecular biology.

[38]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[39]  R. Graziano,et al.  FcγR in Cytotoxicity Exerted by Mononuclear Cells (Part 2 of 2) , 1989 .

[40]  D. Macdonald,et al.  Expression of selectin ligands by cutaneous squamous cell carcinoma. , 1993, The American journal of pathology.

[41]  M. Tallman.  Monoclonal antibody therapies in leukemias. , 2002, Seminars in hematology.

[42]  A. Dorner,et al.  High level synthesis of immunoglobulins in Chinese hamster ovary cells. , 1990, Journal of immunology.

[43]  K. Shitara,et al.  Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma , 2004, Cancer Research.

[44]  C. Cordon-Cardo,et al.  Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. , 1986, Cancer research.

[45]  C. Ballaré,et al.  Differential lytic and agglutinating activity of the anti-Lewisx monoclonal antibody FC-2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studies , 1999, Cancer Immunology, Immunotherapy.

[46]  R. Graziano,et al.  Cytotoxicity mediated by human Fc receptors for IgG. , 1989, Immunology today.

[47]  K. Hellström,et al.  Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. , 1990, Cancer research.

[48]  R. W. Baldwin,et al.  Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting , 2004, Cancer and Metastasis Reviews.

[49]  K. Shitara,et al.  Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism , 2004, Clinical Cancer Research.